33-506 :Special Drug Use-Results Survey of OPDIVO

33-506 :Special Drug Use-Results Survey of OPDIVO (Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2041240115

Enrollment

Registered

2024-10-30

Start date

2024-07-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma, who have recieved OPDIVO for the first time

Exclusion criteria

Exclusion criteria: Patients who have received OPDIVO previously

Design outcomes

Primary

Measure	Time frame
'[Efficacy] Comprehensive improvement (the best antitumor efficacy (RECIST) for 6 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)	—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results